Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Front Endocrinol (Lausanne) ; 12: 727320, 2021.
Article in English | MEDLINE | ID: covidwho-1497068

ABSTRACT

Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that has caused a worldwide pandemic. The majority of medullary thyroid cancers present as a thyroid nodule. At the time of diagnosis, cervical lymph nodes and distant metastases are frequently detected. Case Report: Here, we present a case of a 46-year-old man with coronavirus disease (COVID) pneumonia, who had persistently high serum procalcitonin levels despite normal C-reactive protein levels. The attending infectologist happened to be a colleague who spent some time, as part of her internal medicine rotation, in the Endocrine Ward and recalled that medullary thyroid cancer might be the cause. This led to the timely workup and treatment of the medullary cancer.


Subject(s)
COVID-19/complications , Carcinoma, Neuroendocrine/blood , Carcinoma, Neuroendocrine/diagnosis , Endocrinology/methods , Procalcitonin/blood , Thyroid Neoplasms/blood , Thyroid Neoplasms/diagnosis , Biomarkers, Tumor/blood , C-Reactive Protein/biosynthesis , Carcinoma, Neuroendocrine/complications , Humans , Incidental Findings , Lymph Nodes/pathology , Male , Middle Aged , SARS-CoV-2 , Thyroid Neoplasms/complications , Thyroid Nodule
2.
Dokl Biochem Biophys ; 496(1): 44-47, 2021 May.
Article in English | MEDLINE | ID: covidwho-1495017

ABSTRACT

The high efficiency of using thermoheliox (inhalation with a high-temperature mixture of helium and oxygen) in the treatment of patients affected by COVID-19 was shown. The dynamics of accumulation of IgG, IgM, and C-reactive protein (CRP) in patients with coronavirus infection in the "working" and control groups was studied experimentally. It was shown that thermoheliox intensifies the synthesis of IgG, IgM, and CRP antibodies, while eliminating the induction period on the kinetic curves of the synthesis of specific antibodies in the IgG form and transfers the synthesis of CRP to a fast phase. The results of experiments confirm the previously obtained data based on the analysis of the kinetic model of the development of coronaviral infection in the human body.


Subject(s)
Antibodies, Viral/immunology , C-Reactive Protein/biosynthesis , COVID-19/metabolism , COVID-19/prevention & control , Immunity/immunology , Vaccination/methods , COVID-19/immunology , Humans , Kinetics , Spike Glycoprotein, Coronavirus/immunology
3.
Magnes Res ; 34(3): 103-113, 2021 Aug 01.
Article in English | MEDLINE | ID: covidwho-1468228

ABSTRACT

The aim of the study was to evaluate the significance of hypomagnesemia in patients with coronavirus disease 2019 (COVID-19) and clarify its possible pathogenesis. A retrospective cohort study was conducted by reviewing 83 patients hospitalized in Guanggu district, Wuhan Third Hospital, China. Clinical histories, laboratory findings and outcome data were collected. Eighteen patients had hypomagnesemia during hospitalization. Fourteen patients were in the critical group and six died. In the critical group, serum magnesium (0.72 ± 0.15 mmol/L) was much lower than that in the moderate and severe groups. At the same time, we also found that several indicators are correlated with the level of magnesium. The level of magnesium was positively associated with the lymphocyte count (r = 0.203, P = 0.004) and platelet count (r = 0.217, P = 0.002) but negatively related to the levels of CRP (r = -0.277, P = 0.000), LDH (r = -0.185, P = 0.011) and α-hydroxybutyrate dehydrogenase (r = -0.198, P = 0.008) in the critical group. Hypomagnesemia might increase symptoms and may be associated with mortality in COVID-19 by affecting enzyme activity and activating the inflammatory response. Thus, magnesium might play a key role in the pathogenesis of COVID-19.


Subject(s)
COVID-19/blood , COVID-19/complications , Magnesium Deficiency/blood , Magnesium Deficiency/complications , Magnesium/blood , Adult , Aged , Aged, 80 and over , C-Reactive Protein/biosynthesis , China/epidemiology , Female , Hospitalization , Humans , Hydroxybutyrate Dehydrogenase/blood , Inflammation , L-Lactate Dehydrogenase/blood , Lymphocyte Count , Lymphocytes/cytology , Male , Middle Aged , Platelet Count , Retrospective Studies , Risk Factors , SARS-CoV-2 , Temperature , Treatment Outcome
4.
Chem Biol Interact ; 334: 109339, 2021 Jan 25.
Article in English | MEDLINE | ID: covidwho-970426

ABSTRACT

Clinical trials of thermoheliox application (inhalation with a high-temperature mixture of oxygen and helium, 90 °C) in the treatment of the acute phase of coronavirus infection were conducted. Dynamics of disease development in infected patients (PCR test for the virus) and, dynamics of changes in blood concentration of C-reactive protein, immunoglobulin M, specific immunoglobulin G were studied. High efficiency of thermoheliox in releasing the organism from the virus and stimulating the immune response (thermovaccination effect) was shown. The kinetic model of the process is proposed and analyzed.


Subject(s)
COVID-19/immunology , COVID-19/therapy , Helium/administration & dosage , Hyperthermia, Induced/methods , Oxygen/administration & dosage , Administration, Inhalation , Adult , Aged , Antibodies, Viral/blood , C-Reactive Protein/biosynthesis , COVID-19/virology , Hot Temperature , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Kinetics , Middle Aged , Models, Immunological , SARS-CoV-2/immunology , Vaccination/methods
5.
J Cardiovasc Pharmacol Ther ; 26(3): 244-252, 2021 May.
Article in English | MEDLINE | ID: covidwho-992304

ABSTRACT

BACKGROUND: Speculations whether treatment with angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) predisposes to severe coronavirus disease 2019 (COVID-19) or worsens its outcomes. This study assessed the association of ACE-I/ARB therapy with the development of severe COVID-19. METHODS: This multi-center, prospective study enrolled patients hospitalized for COVID-19 and receiving one or more antihypertensive agents to manage either hypertension or cardiovascular disease. ACE-I/ARB therapy associations with severe COVID-19 on the day of hospitalization, intensive care unit (ICU) admission, mechanical ventilation and in-hospital death on follow-up were tested using a multivariate logistic regression model adjusted for age, obesity, and chronic illnesses. The composite outcome of mechanical ventilation and death was examined using the adjusted Cox multivariate regression model. RESULTS: Of 338 enrolled patients, 245 (72.4%) were using ACE-I/ARB on the day of hospital admission, and 197 continued ACE-I/ARB therapy during hospitalization. Ninety-eight (29%) patients had a severe COVID-19, which was not significantly associated with the use of ACE-I/ARB (OR 1.17, 95% CI 0.66-2.09; P = .57). Prehospitalization ACE-I/ARB therapy was not associated with ICU admission, mechanical ventilation, or in-hospital death. Continuing ACE-I/ARB therapy during hospitalization was associated with decreased mortality (OR 0.22, 95% CI 0.073-0.67; P = .008). ACE-I/ARB use was not associated with developing the composite outcome of mechanical ventilation and in-hospital death (HR 0.95, 95% CI 0.51-1.78; P = .87) versus not using ACE-I/ARB. CONCLUSION: Patients with hypertension or cardiovascular diseases receiving ACE-I/ARB therapy are not at increased risk for severe COVID-19 on admission to the hospital. ICU admission, mechanical ventilation, and mortality are not associated with ACE-I/ARB therapy. Maintaining ACE-I/ARB therapy during hospitalization for COVID-19 lowers the likelihood of death. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT4357535.


Subject(s)
Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , COVID-19/epidemiology , COVID-19/physiopathology , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/epidemiology , Adult , Age Factors , Aged , Aged, 80 and over , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , C-Reactive Protein/biosynthesis , COVID-19/mortality , Female , Hematologic Tests , Hospital Mortality , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Intensive Care Units/statistics & numerical data , Logistic Models , Male , Middle Aged , Obesity/epidemiology , Prospective Studies , Respiration, Artificial/statistics & numerical data , SARS-CoV-2 , Severity of Illness Index
6.
Epidemiol Infect ; 148: e164, 2020 07 27.
Article in English | MEDLINE | ID: covidwho-679966

ABSTRACT

The emergence of 2019 novel coronavirus disease (COVID-19) is currently a global concern. In this study, our goal was to explore the changing expression levels of acute-phase reaction proteins (APRPs) in the serum of COVID-19 patients and to elucidate the immunological characteristics of COVID-19. In the study design, we recruited 72 COVID-19 patients, including 22 cases of mild degree, 38 cases of moderate degree and 12 cases of severe degree. We also recruited 20 patients with community-acquired pneumonia (CAP) and 20 normal control subjects as a comparison. Fasting venous blood was taken to detect the content of complement 3 (C3), complement 4 (C4), C-reactive protein (CRP), serum amyloid A (SAA) and prealbumin (PA). When compared the COVID-19 group with the CAP and normal control groups, respectively, the mean value of CRP and SAA in the COVID-19 group (including mild, moderate and severe patients) had increased significantly (P < 0.01), whereas the mean values of C3, C4 and PA decreased (P < 0.01). For the asymptomatic or mild symptomatic patients with COVID-19, the actual aggravation of disease may be more advanced than the clinical appearances. Meanwhile, the statistical analyses indicated that the development of COVID-19 brought about a significant increase in the content of CRP and SAA (P < 0.01), and a decline in the content of C3, C4 and PA (P < 0.01). These findings suggested that the changes in the level of APRPs could be used as indicators to identify the degree and progression of COVID-19, and the significant changes might demonstrate the aggravation of disease. This study provided a new approach to improve the clinical management plan and prognosis of COVID-19.


Subject(s)
Acute-Phase Proteins/analysis , Acute-Phase Proteins/biosynthesis , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Adult , Aged , C-Reactive Protein/analysis , C-Reactive Protein/biosynthesis , COVID-19 , Case-Control Studies , Community-Acquired Infections/blood , Community-Acquired Infections/immunology , Complement C3/analysis , Complement C3/biosynthesis , Complement C4/analysis , Complement C4/biosynthesis , Coronavirus Infections/blood , Coronavirus Infections/immunology , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia/blood , Pneumonia/immunology , Pneumonia, Viral/blood , Pneumonia, Viral/immunology , Prealbumin/analysis , Prealbumin/biosynthesis , Prognosis , Serum Amyloid A Protein/analysis , Serum Amyloid A Protein/biosynthesis , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL